About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Polr3atm1Iwil
targeted mutation 1, Ian M Willis
MGI:8187813
Summary 2 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cn1
Polr3atm1Iwil/Polr3atm1Iwil
Olig2tm1.1(cre)Wdr/Olig2+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J MGI:8187957
cn2
Polr3atm1Iwil/Polr3atm1Iwil
Tg(CAG-cre/Esr1*)5Amc/0
Not Specified MGI:8188093


Genotype
MGI:8187957
cn1
Allelic
Composition
Polr3atm1Iwil/Polr3atm1Iwil
Olig2tm1.1(cre)Wdr/Olig2+
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Olig2tm1.1(cre)Wdr mutation (1 available); any Olig2 mutation (45 available)
Polr3atm1Iwil mutation (0 available); any Polr3a mutation (70 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
behavior/neurological
• approximately 60% of females fail to differentiate between familiar and novel objects in the object recognition test
• more than 60% of male and approximately 80% of females fail to differentiation between familiar and novel objects in object placement test
• more than 60% of male and approximately 80% of females fail to differentiation between familiar and novel objects in object placement test
• males exhibit a reduction in the magnitude of the startle reflex at all stimulus intensities
• females exhibit a trend in reduced startle reflex at lower stimuli and significant reduction at 115 dB
• both males and females show a delay to elicit a startle reflex at 115 dB
• in the Hargreaves test of reflex response to thermal sensation, mice show normal increased latency for hind paw withdrawal as a function of stimulus intensity, however the relative response is delayed at lower intensities for males and at all intensities for females, suggesting an impaired sensation and reflex response
• mice show a delay in achieving developmental milestones such as deficits in body-righting mechanisms, strength, coordination, locomotion and the extinguishing of pivoting behavior

growth/size/body
• smaller body size throughout adolescence, with males showing decreased size at 3, 4, and 5 weeks of age and females at 4 and 5 weeks of age
• adults exhibit decreased body weight; body weight difference is maintained in males and is enhanced in females between 3 and 5 weeks of age and differences in body weight are seen at 12 and 16 weeks of age
• mice show reduced weight gain after birth, with body weight difference that is more pronounced in males and increases over time from P5 to P21, in contrast to females that maintain a relatively constant and smaller body weight difference

nervous system
• adolescent and adult mice exhibit reduced numbers of myelinating oligodendrocytes
• adolescent males show a reduction in O4 and MOG double-positive premyelinating- oligodendrocytes while females show only a trend in this reduction
• reduced myelin thickness is seen across a range of axon calibers, indicating a defect in the capacity of mature oligodendrocytes to produce a myelin sheath of normal thickness
• reduction in the size of the white matter tract due to the projection of the ventral horns into the ventrolateral funiculus
• myelin sheath thickness is reduced as indicated by a higher average g-ratio
• reduced myelin thickness is seen across a range of axon calibers
• impaired myelination in adolescent and adult mice with hypomyelination in the corpus callosum splenium, hippocampus, and cerebral cortex, and in the ventral and dorsal horns of the spinal cord and a small reduction in the thymus of adolescent mice but not adults
• however, no differences in myelination in the cerebellum and in Purkinje cell number
• fractional anisotropy is reduced in the anterior commissure, corpus callosum genu and splenium, and the optic tract due to increased radial diffusivity in the absence of effects on axial diffusivity, suggesting a myelin deficiency in these regions
• the optic nerve shows no change in fractional anisotropy but reduced radial diffusivity, axial diffusivity, and mean diffusivity
• mice show an increase in the number of unmyelinated axons with cross-sectional axons greater than the smaller myelinated axons in wild-type mice

cellular
• adolescent and adult mice exhibit reduced numbers of myelinating oligodendrocytes
• adolescent males show a reduction in O4 and MOG double-positive premyelinating- oligodendrocytes while females show only a trend in this reduction
• reduced myelin thickness is seen across a range of axon calibers, indicating a defect in the capacity of mature oligodendrocytes to produce a myelin sheath of normal thickness

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
hypomyelinating leukodystrophy 7 DOID:0060794 OMIM:607694
J:311745




Genotype
MGI:8188093
cn2
Allelic
Composition
Polr3atm1Iwil/Polr3atm1Iwil
Tg(CAG-cre/Esr1*)5Amc/0
Genetic
Background
Not Specified
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Polr3atm1Iwil mutation (0 available); any Polr3a mutation (70 available)
Tg(CAG-cre/Esr1*)5Amc mutation (11 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
adipose tissue
• tamoxifen-treated mice show a reduction in subcutaneous adipose tissue at P90, but not at P45
• tamoxifen-treated mice show a reduction in visceral adipose tissue at P90, but not at P45

behavior/neurological
• individual orientation behaviors are lower at P42, P49, P56, and P63, except for orient-shuffle at P42 which shows a trend towards lower performance, indicating that mice spend less time assessing risk at all time points
• however, tamoxifen-treated mice show no differences in anxiety-like behavior
• tamoxifen-treated mice spend less time grooming their legs and back starting at P49 and progressing to P63 and head grooming is reduced at P63
• tamoxifen-treated mice spend less time rearing at most time points, indicating lower levels of exploration
• overall locomotor activity is decreased in tamoxifen-treated mice, with reduced track length at P42, P49, P56, and P63 and mice spend less time running and more time standing still at all time points

digestive/alimentary system
• tamoxifen-treated mice exhibit pronounced and severe exocrine pancreatic atrophy at P42 and P90, respectively

endocrine/exocrine glands
• tamoxifen-treated mice exhibit pronounced and severe exocrine pancreatic atrophy at P42 and P90, respectively

growth/size/body
• mice administered five tamoxifen injections every other day starting at P28 exhibit lower body weight, with weight differences appearing at P34 and becoming progressively larger as mice lose weight over time while controls gain weight over time

hematopoietic system
• tamoxifen-treated mice show reactive microglia in cerebra, as evidenced by the increased cell density and enlarged cell bodies and shorter, thicker processes of Iba1-stained cells in the cortex and particularly in the striatum

homeostasis/metabolism
N
• tamoxifen-treated mice show normal blood glucose concentrations upon feeding and in either the fasted or the refed state and normal glucose tolerance

immune system
• tamoxifen-treated mice show reactive microglia in cerebra, as evidenced by the increased cell density and enlarged cell bodies and shorter, thicker processes of Iba1-stained cells in the cortex and particularly in the striatum

integument
• tamoxifen-treated mice show a reduction in subcutaneous adipose tissue at P90, but not at P45

nervous system
• gene-expression analysis indicates a reduction in oligodendrocytes in tamoxifen-treated mice
• tamoxifen-treated mice show reactive microglia in cerebra, as evidenced by the increased cell density and enlarged cell bodies and shorter, thicker processes of Iba1-stained cells in the cortex and particularly in the striatum
• gene-expression analysis of tamoxifen-treated mice indicates a reduction in neurons in cerebra at P75 and the cerebral cortex shows a reduced number of NeuN+ neurons, indicating cerebral neurodegeneration
• tamoxifen-treated mice show impaired myelin deposition in the hippocampus, and thalamus (cerebrum) in adolescent (P42) and adult (P90) mice and in the cortex at P90
• however, no differences in myelin in the cerebellum, granular cell layer neurons or Purkinje cell density are seen

cellular
• gene-expression analysis indicates a reduction in oligodendrocytes in tamoxifen-treated mice
• tamoxifen-treated mice show reactive microglia in cerebra, as evidenced by the increased cell density and enlarged cell bodies and shorter, thicker processes of Iba1-stained cells in the cortex and particularly in the striatum

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
hypomyelinating leukodystrophy 7 DOID:0060794 OMIM:607694
J:364909





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
03/18/2025
MGI 6.24
The Jackson Laboratory